Ray Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for RTx-015 in Retinitis Pigmentosa

BERKELEY, Calif.--(BUSINESS WIRE)--Ray Therapeutics (RayTx), a clinical-stage biopharmaceutical company pioneering optogenetic therapies for those living with retinal degenerative diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to its lead candidate, RTx-015, for the treatment of retinitis pigmentosa (RP). "Receiving RMAT designation is a critical step as we move along the continuum of progress towa